TIL
Instil Bio, Inc.11.25
+0.13+1.17%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
76.30MP/E (TTM)
-Basic EPS (TTM)
-11.35Dividend Yield
0%Recent Filings
8-K
10-Q
Q3 FY2025 results
Instil Bio narrowed its Q3 operating loss to $15.0M from $23.6M y/y, driven by lower G&A and no repeat IPR&D hit, while ramping AXN-2510/IMM2510 R&D to $9.0M from $0.4M. Net loss improved to $13.6M ($2.01/share) versus $23.0M ($3.54/share), reconciling to 6.8M diluted shares. Tarzana facility rental income jumped to $2.2M, offsetting $1.6M interest on $85.6M loan (6.35%, due Dec 2026). Cash and investments stood at $83.4M after $29.5M op cash burn; assets held for sale hit $112.1M. Non-GAAP metrics not disclosed in the 10-Q. Crowded bispecific field poses stiff competition.
8-K
Q3 results; Phase 1 dosing
Instil Bio reported Q3 2025 results, with cash at $83.4M funding operations beyond 2026, down from $115.1M year-end 2024. R&D expenses jumped to $9.1M from $0.6M, driving net loss of $13.6M or $2.01/share, improved from $23.0M prior year. First patient dosed in Phase 1 '2510 monotherapy trial for solid tumors. Cash burn accelerated.
10-Q
Q2 FY2025 results
Instil Bio's Q2 FY2025 results showed a net loss of $21.4 million, up 43% y/y from $14.9 million, driven by $10.0 million in-process R&D from a milestone payment to ImmuneOnco for AXN-2510/IMM2510's U.S. IND clearance, while research and development expenses rose 131% y/y to $6.7 million on collaboration activities but general and administrative costs fell 42% y/y to $6.2 million amid headcount reductions. Operating loss widened to $23.4 million from $14.1 million y/y, with diluted EPS at $(3.24) versus $(2.29), reconciling to 6.6 million weighted shares. Liquidity stood solid at $103.6 million in cash equivalents, marketable securities, and long-term investments, supporting operations beyond 2026, offset by $84.4 million net debt at 6.35% maturing December 2026; the Tarzana facility, generating $2.2 million quarterly rental income, was listed for sale in March 2025 after $16.6 million YTD impairment. Restructuring under the 2024 Plan continues to streamline costs. Clinical progress includes planned Phase 1 initiation for AXN-2510/IMM2510 in relapsed/refractory solid tumors by year-end. Yet competition in bispecific antibodies remains fierce.
8-K
Instil Bio Q2 results and IND clearance
Instil Bio reported Q2 2025 financials, showing $103.6 million in cash and equivalents, down from $115.1 million at year-end 2024, yet sufficient to fund operations beyond 2026. The FDA cleared the IND for AXN-2510/IMM2510 in July, paving the way for U.S. trial initiation by year-end, while ImmuneOnco's updated monotherapy data in squamous-NSCLC hits the WCLC in September. Net loss widened to $21.4 million from $14.9 million last year. Cash burn accelerates R&D.
ESLA
Estrella Immunopharma, Inc.
1.63-0.18
IBO
Impact BioMedical, Inc.
0.44-0.02
IMA
ImageneBio, Inc.
6.25+0.08
IMMX
Immix Biopharma, Inc.
5.94-0.27
IMNM
Immunome, Inc.
23.48+0.84
IMRX
Immuneering Corporation
5.74-0.04
INMB
INmune Bio Inc.
1.89-0.02
MAIA
MAIA Biotechnology, Inc.
1.23-0.12
NBTX
Nanobiotix S.A.
22.32+0.18
XLO
Xilio Therapeutics, Inc.
0.65+0.00